Enteris BioPharma
MOD3 Pharma is a fully integrated contract development and manufacturing organization (CDMO) specializing in innovative drug delivery solutions for Orally Inhaled and Nasal Drug Products (OINDP). Supported by decades of CMC experience, the company focuses on transforming investigational drugs into clinic-ready products through stage-appropriate methodologies, advanced formulation science, and quality manufacturing. As a subsidiary of SWK Holdings, MOD3 Pharma emphasizes regulatory excellence, scientific innovation, and collaborative partnerships to accelerate drug development from feasibility to early phase clinical trials.
Industries
Nr. of Employees
small (1-50)
Enteris BioPharma
Patents
Services
Regulatory and CMC consulting for drug development, including Module 3 preparation, CMC strategy, and project-level problem solving across development stages.
Formulation development, spray drying, particle engineering, and analytical method development and validation to advance drug products toward clinic readiness.
cGMP manufacture of clinical trial materials, small-batch commercial supplies, finished product release and stability testing, labeling, and blinding for early-phase studies.
Regulatory and CMC consulting for drug development, including Module 3 preparation, CMC strategy, and project-level problem solving across development stages.
Formulation development, spray drying, particle engineering, and analytical method development and validation to advance drug products toward clinic readiness.
cGMP manufacture of clinical trial materials, small-batch commercial supplies, finished product release and stability testing, labeling, and blinding for early-phase studies.
Expertise Areas
- Orally inhaled and nasal drug product (OINDP) development
- Chemistry, Manufacturing and Controls (CMC) strategy
- Early-phase clinical supply manufacturing (Phase 1 & 2)
- Formulation science and bioavailability enhancement
Key Technologies
- Spray drying
- Particle engineering / post-processing
- Semi-automated filling and assembly
- Single-dose and multi-dose nasal delivery systems
News & Updates
MOD3 Pharma joins the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) to advance inhalation science and regulatory excellence.
Schedule a meeting with MOD3 Pharma's team at RDD Europe 2025 to discuss how they can support your OINDP projects through early clinical trials.
Enteris BioPharma, a fully integrated contract development and manufacturing organization, has rebranded as MOD3 Pharma to better reflect its core competencies in supporting Phase 1 & 2 clinical trials for nasal sprays and powders.
MOD3 Pharma joins the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) to advance inhalation science and regulatory excellence.
Schedule a meeting with MOD3 Pharma's team at RDD Europe 2025 to discuss how they can support your OINDP projects through early clinical trials.
Enteris BioPharma, a fully integrated contract development and manufacturing organization, has rebranded as MOD3 Pharma to better reflect its core competencies in supporting Phase 1 & 2 clinical trials for nasal sprays and powders.